Last reviewed · How we verify
aspirin and omeprazole
Aspirin and omeprazole, marketed by Assaf-Harofeh Medical Center, is a combination therapy currently available in the market. The key composition patent is set to expire in 2028, providing a period of exclusivity and potential revenue protection. The primary risk is the lack of reported key trial results and revenue data, which may limit the drug's competitive positioning and investor confidence.
At a glance
| Generic name | aspirin and omeprazole |
|---|---|
| Sponsor | Assaf-Harofeh Medical Center |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- A Trial of Omeprazole and Low Dose Aspirin to Identify Colorectal Biomarkers of Preventive Efficacy (EARLY_PHASE1)
- A Study of Esomeplazole (D961H) in Japanese Paediatric Patients With Reflux Esophagitis, Gastric Ulcer or Duodenal Ulcer (PHASE3)
- A Phase III, Randomized, Study of Aspirin and Esomeprazole Chemoprevention in Barrett's Metaplasia (PHASE3)
- PROUD Study - Preventing Opioid Use Disorders (PHASE4)
- Bendamustine in Combination With Lenalidomide and Dexamethasone in Refractory or Relapsed Multiple Myeloma (PHASE1)
- A Study to Evaluate the Incidence of Gastric Ulcers Following Administration of Either PA32540 or Enteric Coated Aspirin 325 mg in Subjects Who Are at Risk for Developing Aspirin-Associated Ulcers (PHASE3)
- Study to Evaluate the Incidence of Gastric Ulcers Following Administration of Either PA32540 or Enteric Coated Aspirin 325 mg in Subjects Who Are at Risk for Developing Aspirin-Associated Ulcers (PHASE3)
- Study to Evaluate the Long-Term Safety of PA32540 in Subjects Who Are at Risk for Developing Aspirin-Associated Gastric Ulcers (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- aspirin and omeprazole CI brief — competitive landscape report
- aspirin and omeprazole updates RSS · CI watch RSS
- Assaf-Harofeh Medical Center portfolio CI